Innovent Biologics, Inc. (1801.HK)
1801.HK Stock Price Chart
Explore Innovent Biologics, Inc. interactive price chart. Choose custom timeframes to analyze 1801.HK price movements and trends.
1801.HK Company Profile
Discover essential business fundamentals and corporate details for Innovent Biologics, Inc. (1801.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Oct 2018
Employees
5.66K
Website
https://www.innoventbio.comCEO
De-Chao Yu
Description
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
1801.HK Financial Timeline
Browse a chronological timeline of Innovent Biologics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 24 Mar 2026
Earnings released on 27 Aug 2025
EPS came in at $0.56 surpassing the estimated $0.20 by +182.96%, while revenue for the quarter reached $5.73B , missing expectations by -7.70%.
Earnings released on 26 Mar 2025
EPS came in at $0.19 surpassing the estimated -$0.24 by +179.33%, while revenue for the quarter reached $5.82B , beating expectations by +17.52%.
Earnings released on 28 Aug 2024
EPS came in at -$0.26 surpassing the estimated -$0.27 by +4.00%, while revenue for the quarter reached $4.24B , beating expectations by +4.44%.
Earnings released on 20 Mar 2024
EPS came in at -$0.62 falling short of the estimated -$0.55 by -12.90%, while revenue for the quarter reached $3.88B , missing expectations by -52.81%.
Earnings released on 23 Aug 2023
EPS came in at -$0.10 surpassing the estimated -$0.78 by +87.40%, while revenue for the quarter reached $2.92B , beating expectations by +3.63%.
Earnings released on 28 Mar 2023
EPS came in at -$0.92 surpassing the estimated -$1.34 by +30.85%, while revenue for the quarter reached $2.64B , missing expectations by -59.65%.
Earnings released on 30 Jun 2022
EPS came in at -$0.76 surpassing the estimated -$1.19 by +36.44%, while revenue for the quarter reached $2.62B , beating expectations by +6.45%.
Earnings released on 31 Dec 2021
EPS came in at -$1.45 falling short of the estimated -$1.12 by -29.45%, while revenue for the quarter reached $2.85B , beating expectations by +13.92%.
Earnings released on 30 Jun 2021
EPS came in at -$0.83 falling short of the estimated -$0.29 by -188.04%, while revenue for the quarter reached $2.33B , missing expectations by -2.63%.
Earnings released on 31 Dec 2020
EPS came in at -$0.33 falling short of the estimated $0.46 by -171.95%, while revenue for the quarter reached $3.40B , beating expectations by +1.27%.
1801.HK Stock Performance
Access detailed 1801.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.